{"meta":{"query_hash":"a725087dc833","filters":{"venue":"The Prostate Journal"},"cohort_total":2,"direct_labels_cover":0,"predictions_cover":2,"exported":2,"export_cap":100000,"truncated":false,"label_status":"direct model label, unvalidated","prediction_status":"machine_predicted_unvalidated (Codex and Gemma teacher distillation)","score_status":"score_only:v0-immature-baseline","snapshot":{"source":"OpenAlex, pinned release, all 482 partitions","release":"2026-06-24","frame_built":"2026-07-12"},"permalink":"https://metacan.xera.ac/q/a725087dc833","api":"https://metacan.xera.ac/api/v1/cohort?venue=The+Prostate+Journal"},"results":[{"id":"W1975423257","doi":"10.1046/j.1525-1411.2000.22007.x","title":"PSP94: Evaluation of Prognostic Utility in Patients Treated with Radiotherapy for Nonmetastatic Prostate Cancer","year":2000,"lang":"en","type":"article","venue":"The Prostate Journal","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"London Health Sciences Centre","funders":"","keywords":"Prostate cancer; Medicine; Radiation therapy; Internal medicine; Prostate; Prostate-specific antigen; Oncology; Univariate analysis; Cancer; Subgroup analysis; Urology; Gastroenterology; Confidence interval; Multivariate analysis","score_opus":0.02879504236025441,"score_gpt":0.31913123053407777,"score_spread":0.29033618817382334,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1975423257","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9994087,0.00027439278,0.00007552195,0.000029163852,0.00000265031,0.0000037654781,0.00005610217,0.0000048998254,0.0001447651],"genre_scores_gemma":[0.99975795,0.000042157313,0.000056550612,0.000006703378,0.0000069102066,0.0000024214946,0.00008354635,7.4727654e-7,0.000042861317],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99978834,0.00008429512,0.0000218718,0.000032166055,0.000044393008,0.000028980789],"domain_scores_gemma":[0.9991462,0.00021918298,0.00034020454,0.000031966225,0.000078300785,0.00018417918],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00038282308,0.00027775436,0.00034849645,0.0004508344,0.00025316337,0.00034082666,0.00027265534,0.0003170324,0.001420207],"category_scores_gemma":[0.0019692387,0.00013344316,0.00022964767,0.00051606365,0.000244839,0.00022595235,0.0002338944,0.00039472946,0.0002048629],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00045399362,0.000019873349,0.99657357,0.000010257257,0.000029832916,0.00008375359,0.000019126419,0.000072065,0.0006664831,0.00000422389,0.000044328783,0.0020224596],"study_design_scores_gemma":[0.000019902847,0.0003633762,0.99776924,0.000003795418,0.00003475149,0.0008264947,0.000055214136,0.0005068196,0.0003197142,0.000013007697,0.00008473764,0.00000313325],"about_ca_topic_score_codex":0.0010495175,"about_ca_topic_score_gemma":0.0015437367,"teacher_disagreement_score":0.001420207,"about_ca_system_score_codex":0.00020403013,"about_ca_system_score_gemma":0.00024707642,"threshold_uncertainty_score":0.0047510266},"labels":[],"label_agreement":null},{"id":"W2144087378","doi":"10.1046/j.1525-1411.2000.23003.x","title":"Bicalutamide and Flutamide, Each in Combination with Luteinizing Hormone‐Releasing Hormone Analogs, in Advanced Prostate Cancer: Exploratory Analysis of Impact of Extent of Disease by Bone Scan on Outcome","year":2000,"lang":"en","type":"article","venue":"The Prostate Journal","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Cancer Foundation","funders":"AstraZeneca","keywords":"Bicalutamide; Medicine; Flutamide; Antiandrogen; Prostate cancer; Internal medicine; Oncology; Hazard ratio; Urology; Cancer; Endocrinology; Confidence interval; Androgen receptor","score_opus":0.01753570239040011,"score_gpt":0.3190161873781584,"score_spread":0.3014804849877583,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2144087378","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9985514,0.0010872146,0.000107043634,0.000022785689,0.000007719999,0.000069844,0.000051954066,0.0000029910248,0.00009894528],"genre_scores_gemma":[0.9991972,0.00026037352,0.00021705408,0.00002931731,0.00003232584,0.00008863715,0.000095393334,0.0000012006519,0.000078645746],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9980381,0.001388021,0.00010242989,0.00015718435,0.00019362845,0.00012069316],"domain_scores_gemma":[0.99767655,0.0012340525,0.00050109305,0.00016213031,0.00007097155,0.00035519022],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002836782,0.00063240115,0.0016345154,0.0004020563,0.00017334353,0.00053265557,0.00042744662,0.0005959569,0.0008098825],"category_scores_gemma":[0.0018839551,0.00028925875,0.0018369377,0.00037276847,0.0006308474,0.0003821625,0.00030257565,0.00076765224,0.00011752709],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.89270043,0.008500621,0.042137876,0.000409296,0.003721238,0.00013259286,0.00008933356,0.0020579663,0.0139375655,0.00007038046,0.0001339808,0.036108747],"study_design_scores_gemma":[0.12519805,0.73364246,0.12809221,0.00006285321,0.003169019,0.00032491548,0.000093150324,0.002718696,0.0058998526,0.00019548519,0.0005583687,0.000044936947],"about_ca_topic_score_codex":0.00034041263,"about_ca_topic_score_gemma":0.000788157,"teacher_disagreement_score":0.002836782,"about_ca_system_score_codex":0.0004950289,"about_ca_system_score_gemma":0.0006005693,"threshold_uncertainty_score":0.015002489},"labels":[],"label_agreement":null}]}